Therapeutic potential of angiotensin II receptor antagonists

被引:12
|
作者
White, M [2 ]
Racine, N
Ducharme, A
de Champlain, J
机构
[1] Univ Montreal, Dept Physiol, Montreal, PQ H1T 1C8, Canada
[2] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada
关键词
angiotensin II; angiotensin receptor blockade; cardiovascular function;
D O I
10.1517/13543784.10.9.1687
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The circulating renin angiotensin system plays an important role in cardiovascular homeostasis. More importantly, the local tissue renin angiotensin plays a pivotal role in cell growth and remodelling of cardiomyocytes and on the peripheral arterial vasculature. in addition, the renin angiotensin system is related to apoptosis, control of baroreflex and autonomic responses, vascular remodelling and regulation of coagulation, inflammation and oxidation. The cardioprotective and vascular protective effects of the angiotensin receptive blockade appears to be related to selective blockade of the Type I angiotensin II receptors. However, there is now growing evidence showing that some of the effects of angiotensin II receptor blockers (ARBs) are related to the activation of the kinin pathways. This paper will review some of the recent mechanisms related to the cardiovascular effects of angiotensin and more specifically of ARBs. This paper will present the novel data on the role of ARB in the development of atherosclerosis, vascular remodelling, coagulation balance and autonomic regulation. Finally, the role of ARBs, used alone or in combination with ACE inhibitor in patients with heart failure, will be discussed.
引用
收藏
页码:1687 / 1701
页数:15
相关论文
共 50 条
  • [31] Angiotensin II receptor antagonists in arterial hypertension
    R Hernández-Hernández
    M Velasco
    MJ Armas-Hernández
    MC Armas-Padilla
    Journal of Human Hypertension, 2000, 14 : S69 - S72
  • [32] Angiotensin II receptor antagonists in the treatment of hypertension
    Kaplan, NM
    AMERICAN FAMILY PHYSICIAN, 1999, 60 (04) : 1185 - 1190
  • [33] Angiotensin II receptor antagonists: What future?
    Onuigbo, M
    SOUTHERN MEDICAL JOURNAL, 1998, 91 (08) : 794 - 796
  • [34] Angiotensin II receptor antagonists and portal hypertension
    Lebrec, D
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2002, 26 (03): : 254 - 255
  • [35] Angiotensin II receptor antagonists: are they all the same?
    Mounier-Vehier, C
    Devos, P
    PRESSE MEDICALE, 2001, 30 (21): : 1072 - 1075
  • [36] NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS
    NAKA, T
    KUBO, K
    FURUKAWA, Y
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1995, 53 (09) : 802 - 810
  • [37] DIHYDROPYRIMIDINE ANGIOTENSIN-II RECEPTOR ANTAGONISTS
    ATWAL, KS
    AHMED, SZ
    BIRD, JE
    DELANEY, CL
    DICKINSON, KEJ
    FERRARA, FN
    HEDBERG, A
    MILLER, AV
    MORELAND, S
    OREILLY, BC
    SCHAEFFER, TR
    WALDRON, TL
    WELLER, HN
    JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (25) : 4751 - 4763
  • [38] NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS
    STEINBERG, MI
    WIEST, SA
    PALKOWITZ, AD
    CARDIOVASCULAR DRUG REVIEWS, 1993, 11 (03): : 312 - 358
  • [39] Teratogenicity with angiotensin II receptor antagonists in pregnancy
    Boix, E
    Zapater, P
    Picó, A
    Moreno, O
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (11) : 1029 - 1031
  • [40] Teratogenicity with angiotensin II receptor antagonists in pregnancy
    E. Boix
    P. Zapater
    A. Picó
    O. Moreno
    Journal of Endocrinological Investigation, 2005, 28 : 1029 - 1031